product
Deramiocel
Also known as CAP-1002
Deramiocel (CAP-1002) is Capricor Therapeutics' investigational cell therapy for Duchenne muscular dystrophy, made from donor heart cells.[1] Capricor reported that its phase 3 HOPE-3 trial met its primary endpoint, slowing the decline in upper limb function by 54% compared with placebo, though an FDA advisory committee voted that the evidence did not support its effectiveness for Duchenne cardiomyopathy.[2][3] The FDA's decision date was moved to 22 November 2026 after Capricor narrowed its proposed use to upper limb function.[4]
Key facts
Deramiocel, also called CAP-1002, is an investigational cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. It is made of allogeneic cardiosphere-derived cells, which come from donor heart tissue.[1] Capricor describes Duchenne as a severe X-linked genetic disorder of progressive muscle degeneration, caused by the absence of functional dystrophin.[5] In the US, deramiocel holds Orphan Drug, Regenerative Medicine Advanced Therapy and Rare Pediatric Disease designations.[6]
This page is not medical advice. Families considering treatment should talk to their care team.
The HOPE-3 trial
HOPE-3 was a randomized, double-blind, placebo-controlled phase 3 trial of 106 patients. Capricor reported that it met its primary endpoint, with deramiocel slowing the decline in upper limb function by 54% compared with placebo (PUL 2.0 scale, p=0.03).[2] The results were published in The Lancet in July 2026.[2]
The advisory committee vote
At a July 2026 meeting, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted that the available evidence did not support deramiocel’s effectiveness for cardiomyopathy, the heart disease that comes with Duchenne. The vote was non-binding. Capricor said the question covered a narrower indication than it had proposed.[3] Capricor also said the committee’s separate discussion of upper limb function was directionally supportive of the HOPE-3 evidence.[7]
A narrower application and a later date
After the meeting, Capricor sent the FDA 24-month open-label data from HOPE-3 and asked it to consider a refined indication focused on upper limb function. In August 2026 the FDA classed the submission as a major amendment and moved its decision date from 22 August to 22 November 2026.[4] Capricor also reported that an FDA inspection of trial records in July 2026 produced a Form 483 with one observation. The company said it had responded and, as of November, was awaiting feedback.[8] For how this kind of review works, see how FDA drug approval works.
What to watch
The next milestone is the FDA’s action, due by 22 November 2026.[4]
Read next
Health in 2026: a crash course
How drugs are tested and approved, who regulates them, and where to start on cholesterol, diabetes, dementia, ALS and cancer screening.
Questions readers ask
What is deramiocel?
An investigational cell therapy from Capricor Therapeutics, made of allogeneic (donor-derived) cardiosphere-derived cells, being developed for Duchenne muscular dystrophy.[1]
What did the HOPE-3 trial find?
Capricor reported that the 106-patient, placebo-controlled phase 3 trial met its primary endpoint, with deramiocel slowing the decline in upper limb function by 54% compared with placebo. The results were published in The Lancet in July 2026.[2]
What did the FDA advisory committee decide?
In July 2026 the committee voted that the evidence did not support deramiocel's effectiveness for cardiomyopathy in Duchenne. The vote was non-binding, and Capricor said it covered a narrower indication than it had proposed and that the committee's discussion of upper limb function was directionally supportive.[3][7]
When will the FDA decide?
The goal date is 22 November 2026. The FDA moved it from 22 August after classing Capricor's new data and narrower proposed use as a major amendment.[4]
Sources
· 8 claims from 1 publisher
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Deramiocel (CAP-1002) is Capricor Therapeutics' investigational cell therapy for Duchenne muscular dystrophy, made of allogeneic (donor-derived) cardiosphere-derived cells from heart tissue. confirmedas of 2026-08-24
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 · About Deramiocel (retrieved 2026-11-14)
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- [2]
Capricor reported that its randomized, double-blind, placebo-controlled phase 3 HOPE-3 trial (106 patients) met its primary endpoint, with deramiocel slowing the decline in upper limb function by 54% compared with placebo (PUL 2.0, p=0.03); the results were published in The Lancet in July 2026. confirmedas of 2026-07-29
- The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-07-29 (retrieved 2026-11-14)
- The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-07-29 (retrieved 2026-11-14)
- [3]
At a July 2026 meeting, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that the available evidence did not support deramiocel's effectiveness for cardiomyopathy in Duchenne muscular dystrophy; the vote was non-binding and, Capricor said, addressed a narrower indication than it had proposed. confirmedas of 2026-07-30
- Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-07-30 (retrieved 2026-11-14)
- Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-07-30 (retrieved 2026-11-14)
- [4]
In August 2026 the FDA classified Capricor's submission of 24-month open-label HOPE-3 data, supporting a refined indication focused on upper limb function, as a major amendment and extended the deramiocel decision date from 22 August 2026 to 22 November 2026. confirmedas of 2026-08-24
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- Capricor Therapeutics third quarter 2026 results press release (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-11-10 (retrieved 2026-11-14)
- [5]
Capricor describes Duchenne muscular dystrophy as a severe X-linked genetic disorder of progressive muscle degeneration caused by the absence of functional dystrophin. confirmedas of 2026-08-24
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- [6]
In the US deramiocel holds Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations for Duchenne muscular dystrophy. confirmedas of 2026-08-24
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-08-24 (retrieved 2026-11-14)
- [7]
Capricor said that in a separate discussion of upper limb function, the advisory committee's feedback was directionally supportive of the HOPE-3 evidence. confirmedas of 2026-07-30
- Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-07-30 (retrieved 2026-11-14)
- [8]
Capricor reported that the FDA carried out a clinical trial (BIMO) inspection in July 2026 and issued a Form 483 with one observation, to which the company had responded and was awaiting feedback as of November 2026. confirmedas of 2026-11-10
- Capricor Therapeutics third quarter 2026 results press release (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-11-10 (retrieved 2026-11-14)
- Capricor Therapeutics third quarter 2026 results press release (Form 8-K exhibit) · Capricor Therapeutics (SEC filing) · Primary source · 2026-11-10 (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 22, 2026.
Cite this page
"Deramiocel." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/deramiocel
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.